Suzhou Immunofoco

Immunofoco is a clinical-stage biotechnology company specializing in the development of innovative CAR-T cell therapies for solid tumors and hematological malignancies. Founded in 2020 by a team of experts from Fosun Kite and Henlius, the company utilizes a "dual-engine" model focusing on both ex vivo and in vivo CAR-T technologies. Its lead candidate, IMC002 (targeting CLDN18.2), is currently in Phase 3 pivotal trials in China and has received RMAT and Fast Track designations from the U.S. FDA. The company's proprietary platforms, including iMagic for in vivo CAR-T generation and Peri Cruiser for reducing on-target, off-tumor toxicity, aim to address the core challenges of treating solid tumors with cellular immunotherapy. Immunofoco operates a vertically integrated value chain with a GMP manufacturing facility in Suzhou and an international operations headquarters in Shenzhen.